An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.
Currently the vaccine is approved only for use in children.
The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.
Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755
Source: MedPage Today